To evaluate the in-vivo preclinical antitumor activity of
sanguinarine in a rat syngeneic model of
colorectal cancer. The effects of
sanguinarine on DHD/K12/TRb colorectal
adenocarcinoma cells were first evaluated in vitro by means of ³H-
thymidine incorporation, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay, and terminal
transferase dUTP nick end labeling (TUNEL) microscopy. For the in-vivo studies, DHD/K12/TRb cells (1.5 × 10⁶ cells/0.3 ml of sterile saline/animal) were injected subcutaneously in syngeneic BDIX rats, which were chronically treated with
sanguinarine (5 mg/kg/day per os) or control diluent.
Tumor growth,
body weight, hematologic, and clinical chemistry measurements were monitored in individual animals at defined time intervals. After killing, subcutaneous
tumors were explanted from experimental animals for histopathological examination. In vitro, micromolar concentrations of
sanguinarine inhibited dose-dependently DHD/K12/TRb cell proliferation and metabolism and induced cell death by apoptosis. In vivo,
oral administration of
sanguinarine induced a significant inhibition of
tumor growth (P<0.01 vs. untreated controls), in the absence of any toxic or side effects. Marked apoptosis and reduced peritumoral vascularization were observed in
tumors from
sanguinarine-treated rats as compared with the controls. Additional basic studies are needed to fully characterize the mechanism/s underlying the inhibitory effects of
sanguinarine on angiogenesis and
tumor growth as well as the pharmacological and safety profile of this
drug in experimental
tumor models. Overall, findings from this study suggest that
sanguinarine is a likely candidate for further evaluation in
cancer therapy.